CINXE.COM

<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head id="Head1"><script type="text/javascript" src="https://web-static.archive.org/_static/js/bundle-playback.js?v=7YQSqjSh" charset="utf-8"></script> <script type="text/javascript" src="https://web-static.archive.org/_static/js/wombat.js?v=txqj7nKC" charset="utf-8"></script> <script>window.RufflePlayer=window.RufflePlayer||{};window.RufflePlayer.config={"autoplay":"on","unmuteOverlay":"hidden"};</script> <script type="text/javascript" src="https://web-static.archive.org/_static/js/ruffle/ruffle.js"></script> <script type="text/javascript"> __wm.init("https://web.archive.org/web"); __wm.wombat("http://www.healio.com/microsite/oncolytic-immunotherapy/home","20130912183510","https://web.archive.org/","web","https://web-static.archive.org/_static/", "1379010910"); </script> <link rel="stylesheet" type="text/css" href="https://web-static.archive.org/_static/css/banner-styles.css?v=p7PEIJWi" /> <link rel="stylesheet" type="text/css" href="https://web-static.archive.org/_static/css/iconochive.css?v=3PDvdIFv" />  <title> Oncolytic Immunotherapy | Home </title><meta id="metaDescription" name="description" content="Oncolytic Immunotherapy (OI) is an innovative research area for cancer therapy, which involves a modified virus that has the potential to induce tumor cell lysis through selective replication, and activate T cells for a specific, systemic immune response. Oncolytic viruses may not only cause direct tumor cell destruction through oncolysis, but may also induce a systemic immune response that targets specific tumor cells throughout the body. Amgen. Leading the way in the study of Oncolytic Immunotherapy."/><meta id="metaKeywords" name="keywords" content="Oncolytic Immunotherapy"/>  <link href="/web/20130912183510cs_/http://www.healio.com/~/media/Microsite/2013/Oncolytic Immunotherapy/Amgen Styles.css" rel="stylesheet" type="text/css"/> <script src="https://web.archive.org/web/20130912183510js_/http://ajax.googleapis.com/ajax/libs/jquery/1.9.1/jquery.min.js" type="text/javascript"></script> <script src="https://web.archive.org/web/20130912183510js_/http://ajax.googleapis.com/ajax/libs/jqueryui/1.10.1/jquery-ui.min.js" type="text/javascript"></script> <script src="https://web.archive.org/web/20130912183510js_/http://cdn.jquerytools.org/1.2.7/full/jquery.tools.min.js" type="text/javascript"></script> <script src="https://web.archive.org/web/20130912183510js_/http://9d7853ee9d6a9fe44627-2e4bb30b5e6df6334257b7b86e5d5413.r87.cf1.rackcdn.com/jquery.modalbox-1.4.4-min.js" type="text/javascript"></script> <script src="https://web.archive.org/web/20130912183510js_/http://9d7853ee9d6a9fe44627-2e4bb30b5e6df6334257b7b86e5d5413.r87.cf1.rackcdn.com/microsite-base.js" type="text/javascript"></script> <script src="https://web.archive.org/web/20130912183510js_/http://f8d1c5bcad5835ea7a1a-269dd8e7393eefd1160eec43610a2b29.r29.cf1.rackcdn.com/jquery.brightcove-video.js" type="text/javascript"></script>  <script src="/web/20130912183510js_/http://www.healio.com/~/media/Microsite/2013/Oncolytic Immunotherapy/Amgen JS.js" type="text/javascript"></script><script type="text/javascript">var NREUMQ=NREUMQ||[];NREUMQ.push(["mark","firstbyte",new Date().getTime()]);</script></head> <body id="Body" class="home"> <form method="post" action="/web/20130912183510/http://www.healio.com/microsite/oncolytic-immunotherapy/home" id="frmMain"> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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"/> </div>  <div id="wrap">  <div id="header"> <div class="utility-nav"> <a href="/web/20130912183510/http://www.healio.com/hematology-oncology" rel="gainternallinks;Amgen Oncolytic Immunotherapy Microsite;Interaction;Return to Healio">Return to <span>Healio</span></a> </div> </div>   <div id="main-content-1col">  <div id="main-content"> <div class="btn"><a rel="gainternallinks;Amgen Oncolytic Immunotherapy Microsite;Interaction;Splash Page Button" href="/web/20130912183510/http://www.healio.com/microsite/oncolytic-immunotherapy/explore">Learn About Oncolytic Immunotherapy</a></div>  <div class="home-col1"> <h1>Amgen Oncology</h1> <p><strong>Amgen is researching ways to help T cells target cancer.</strong></p> <h2>Find it</h2> <p>Oncolytic Immunotherapy (OI) is an innovative research area for cancer therapy, which involves a modified virus that has the potential to induce tumor cell lysis through selective replication, and activate T cells for a specific, systemic immune response.<sup>1-4</sup></p> </div>  <div class="home-col2"> <h2>Fight it</h2> <p>Oncolytic viruses may not only cause direct tumor cell destruction through oncolysis, but may also induce a systemic immune response that targets specific tumor cells throughout the body.<sup>1,5</sup></p> <p><strong><em>Amgen. Leading the way in the study of Oncolytic Immunotherapy.</em></strong></p> </div> </div> </div>   <div id="footer"> <div id="layout_1_belowpagecontent_0_footerCol1" class="col1"> <script type="text/javascript"> /* <![CDATA[ */ $(document).ready(function() { $("ol li").wrapInner("<span style='font-weight:normal' />") }) /* ]]> */ </script> <div id="modal-container-1" style="display:none;"> <h3 class="ref-head">References</h3> <ol class="references"> <li>Pol JG, Ress茅guier J, Lichty BD. Oncolytic viruses: a step into cancer immunotherapy. <em>Virus Adapt Treat</em>. 2012;4:1-21.</li> <li>Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. <em>Lancet Oncol</em>. 2002;3:17-26.</li> <li>Mullen JT, Tanabe KK. Viral oncolysis. Oncologist. 2002;7:106-119.</li> <li>Melcher A, Parato, K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. <em>Mol Ther</em>. 2011;19:1008-1016.</li> <li>Fukuhara H, Todo T. Oncolytic herpes simplex virus type 1 and host immune responses. <em>Curr Cancer Drug Targets</em>. 2007;7:149-155.</li> <li>Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. <em>Cancer Gene Ther</em>. 2005;12:141-161.</li> <li>Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. <em>Mol Ther</em>. 2007;15:651-659.</li> <li>Yervoy庐 (ipilimumab) prescribing information, Bristol-Myers Squibb Company.</li> <li>Proleukin庐 (aldesleukin) prescribing information, Bayer Healthcare Pharmaceuticals.</li> <li>Coley WB. Contribution to the knowledge of sarcoma. <em>Ann Surg</em>. 1891;14:199-220.</li> <li>Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigious). <em>Proc R Soc Med</em>. 1909;10:1-48.</li> <li>Dock G. The influence of complicating diseases upon leukemia. <em>Am J Med Sci</em>. 1904;127:563-592.</li> <li>Hoster HA, Zanes RP Jr, von Haam E. Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease (a preliminary report). <em>Cancer Res</em>. 1949;9:473-480.</li> <li>Bierman HR, Crile DM, Dod KS, et al. Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. <em>Cancer</em>. 1953;6:591-605.</li> <li>Asada T. Treatment of human cancer with mumps virus. <em>Cancer</em>. 1974;34:1907-1928.</li> <li>Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. <em>Ann Surg</em>. 1974;180:635-643.</li> <li>K枚hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. <em>Nature</em>. 1975; 256:495-497.</li> <li>Radov LA, Korn JH, Haskill JS. Host immune potentiation of drug responses to a murine mammary adenocarcinoma. II. Effect of melphalan therapy on the host immune system. <em>Int. J Cancer</em>. 1976;18:630-638.</li> <li>Haskill JS, Fett JW. Possible evidence for antibody-dependent macrophage-mediated cytotoxicity directed against murine adenocarcinoma cells in vivo. <em>J Immunol</em>. 1976;117:1992-1998.</li> <li>Martinis J, Croce CM. Somatic cell hybrids producing antibodies specific for the tumor antigen of simian virus 40. <em>Proc Natl Acad Sci USA</em>. 1978;75:2320-2323.</li> <li>Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. <em>Science</em>. 1986;233:1318-1321.</li> <li>Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. <em>Oncologist</em>. 2001;6:34-55.</li> <li>Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. <em>Science</em>. 1991;252:854-856.</li> <li>US Food and Drug Administration website. Approved products: vaccines, blood & biologics. August 21, 1998 Approval Letter鈥擝CG Vaccine. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101486.htm. Accessed March 17, 2013.</li> <li>Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol. 2008;26:1774-1777.</li> <li>US Food and Drug Administration website. Approved products: vaccines, blood & biologics. April 29, 2010 Approval Letter鈥擯rovenge庐. http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm. Accessed March 17, 2013.</li> <li>US Food and Drug Administration website. BLA Approval March 25, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125377s000ltr.pdf. Accessed March 17, 2013.</li> <li>Flinn R. Modified smallpox vaccine stymies liver cancer in study. Bloomberg website. http://mobile.bloomberg.com/news/2013-02-10/modified-smallpox-vaccine-stymies-liver-cancer-in-study.html. Accessed March 17, 2013.</li> <li>ClinicalTrials.gov website. Recombinant measles virus vaccine therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer (NCT00408590). http://www.clinicaltrials.gov/ct2/show/NCT00408590?term=ca. Accessed March 17, 2013.</li> <li>ClinicalTrials.gov website. A study of recombinant vaccinia virus to evaluate the safety and efficacy of a transdermal injection within the tumor of patients with primary or metastatic hepatic carcinoma (NCT00629759). http://www.clinicaltrials.gov/ct2/show/NCT00629759?term=NCT00629759&rank=1. Accessed March 17, 2013.</li> <li>ClinicalTrials.gov website. Safety and effectiveness study of G207, a tumor-killing virus, in patients with recurrent brain cancer (NCT00028158). http://www.clinicaltrials.gov/ct2/show/NCT00028158?term=NCT00028158&rank=1. Accessed March 17, 2013.</li> <li>Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. <em>Mol Ther</em>. 2010;18:1275-1283.</li> <li>Miyatake S-I, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. <em>J Virol</em>. 1997;71:5124-5132.</li> <li>Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. <em>Cancer Res</em>. 1997;57:2559-2563.<br/><br/> Yervoy庐 is a registered trademark of Bristol-Myers Squibb Company.<br/> Proleukin庐 is a registered trademark of Novartis Vaccines and Diagnostics, Inc.<br/> Provenge庐 is a registered trademark of Dendreon Corporation. </li> </ol> </div> <a class="modalbox-1" href="javascript:void(0);" rel="gaeventtracking;Amgen Oncolytic Immunotherapy Microsite;Interaction;References Popup">References</a> </div> <div id="layout_1_belowpagecontent_0_footerCol2" class="col2"> <h3>The five stages of oncolytic immunotherapy</h3> </div> <div id="layout_1_belowpagecontent_0_footerCol3" class="col3"> <div class="mod-area"> <div id="modal-container-2" style="display:none;"> <img src="https://web.archive.org/web/20130912183510im_/http://f8d1c5bcad5835ea7a1a-269dd8e7393eefd1160eec43610a2b29.r29.cf1.rackcdn.com/player-popup-art.png" width="948" height="363" alt=""/> </div> <a class="modalbox-2" href="javascript:void(0);" rel="gaeventtracking;Amgen Oncolytic Immunotherapy Microsite;Interaction;Scientific Summary Popup">Scientific summary of ONCOLYTIC IMMUNOTHERAPY</a> </div> <div class="number-code" style="font-size: 11px; margin-top: 40px; text-align: right;">74132-R1-V1</div> </div> </div>  </div>  </div>  </form> <script type="text/javascript"> var _gaq = _gaq || []; _gaq.push(['_setAccount', 'UA-671605-73']); _gaq.push(['_trackPageview']); (function () { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://web.archive.org/web/20130912183510/https://ssl' : 'https://web.archive.org/web/20130912183510/http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); </script> <script type="text/javascript"> if (!NREUMQ.f) {NREUMQ.f=function() {NREUMQ.push(["load",new Date().getTime()]);var e=document.createElement("script"); e.type="text/javascript"; e.src=(("http:"===document.location.protocol)?"http:":"https:") + "//" + "js-agent.newrelic.com/nr-100.js"; document.body.appendChild(e);if(NREUMQ.a)NREUMQ.a();};NREUMQ.a=window.onload;window.onload=NREUMQ.f;};NREUMQ.push(["nrfj","beacon-2.newrelic.com","d03feeacda","1851818","YAEAbEZTCkZZAExeWVlLI2tkHRRHXRBdWUJWEAtXWh0IVEEMTUNFGAkLW0ZdF1xMBksYW14HEFdHWxBQVAJBWENDSgNLREo=",6,59,new Date().getTime(),"1554BCDD4E5844A9","","","",""]);</script></body> </html>